Abstract Library

#4607 BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs

Introduction: There is an unmet clinical need to identify new, effective therapies for patients with neuroendocrine tumours (NETs). Analysis of single-cell expression data revealed that NETs express high levels of the Bcl2 family of antiapoptotic proteins. Therefore, we hypothesised that proapoptotic drugs, such as BH3-mimetics, can induce programmed cell death, i.e., apoptosis, of neuroendocrine cancer cells.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Kale J, Lens A, Tsui H,

Keywords: neuroendocrine tumour, BH3-mimetics, Navitoclax, Cabozantinib, patient-derived organoids, apoptosis, 177Lu-Dotatate,

#4534 Development of new 3D in vitro models for pancreatic neuroendocrine tumours (PanNETs)

Introduction: Current PanNET in vitro models struggle to accurately replicate the tumour’s biology and microenvironment, limiting understanding of the mechanisms underlying PanNET behaviour and drugs response.

Conference:

Presenting Author:

Authors: Battistella A, Pinos R, Barbaglio F, Capurso G, Schiavo Lena M,

Keywords: Preclinical models, Pan NET, microenvironment, bioprinting, tumour slices, drug testing,

#4424 Tumour-derived apolipoprotein E induces tip endothelial cell to remodel tumour stroma ratio and promote pancreatic neuroendocrine tumour progression

Introduction: Current clinical trials have shown that single-targeted matrix administration does not improve patient prognosis. The investigation of targeted matrix administration in combination with other therapies is crucial for effectively managing TSR in pNETs.

Conference:

Presenting Author: Ji S

Authors: Lou X, Ji S, Xu X, Chen J, Yu X,

Keywords: APOE, pancreatic neuroendocrine tumour, endothelial cell, tumour stroma ratio, mTOR inhibitor,

#4282 A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumours and carcinomas

Introduction: Neuroendocrine neoplasms (NENs) consist of neuroendocrine tumours and neuroendocrine carcinomas, which are rare malignancies found in various anatomical sites, including the gastrointestinal tract, pancreatic islets, lungs, and adrenal glands. Poorly differentiated NECs are classified as high-grade carcinomas that bear resemblance to small-cell lung cancer; however, these patients experience a high risk of relapse and demonstrate a limited response to additional systemic therapies. Adrenocortical carcinoma (ACC) is another rare cancer and currently, no targeted therapies have demonstrated significant effectiveness for this condition. Preclinical investigations have indicated that Delta-like non-canonical notch ligand 1 (DLK1) is expressed in various neuroendocrine neoplasms, including ACC, SCLC, neuroblastoma, pheochromocytoma, and paraganglioma.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Glod J, Magee T, Cooper K, Rivero A,

Keywords: NEN, NEC, NET, ACC, ADC, ADCT-701,

#4183 Establishment of novel patient-derived preclinical models for neuroendocrine tumors

Introduction: Neuroendocrine tumors (NETs) arise in different organs and are heterogeneous with limited treatment options. Preclinical models established from patient tumor specimens enable precision oncology by assessing the response to various drug treatments.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Li B, Li Y, Tsui H,

Keywords: preclinical models, patient-derived organoids, patient-derived xenografts, drug screening,